Olaparib Real-world Utilization and Clinical Outcomes in France, Italy, and the UK
Condition(s):Ovary CancerLast Updated:October 10, 2023Active, not recruiting
Hide Studies Not Open or Pending
Condition(s):Ovary CancerLast Updated:October 10, 2023Active, not recruiting
Condition(s):Bladder CancerLast Updated:April 6, 2020Completed
Condition(s):HER2-ve Metastatic Breast Cancer; Germline BRCA1/2 Mutations; Somatic BRCA1/2 MutationsLast Updated:January 17, 2023Completed
Condition(s):Ovarian Cancer; Ovarian and Fallopian Tube Cysts and Neoplasms; Neoplasms by Site; Neoplasms; Genital Neoplasms, Female; Urogenital Neoplasms; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Carcinoma, Ovarian Epithelial; Ovarian Diseases; Adnexal Diseases; Genital Diseases, Female; Carcinoma; Anlotinib; PARP Inhibitors; BRCA1 Mutation; Angiogenesis; Antineoplastic Agents; BRCA2 MutationLast Updated:October 30, 2020Unknown status
Condition(s):MesotheliomaLast Updated:April 9, 2021Completed
Condition(s):Ovarian Cancer; Breast CancerLast Updated:October 31, 2022Completed
Condition(s):Osteosarcoma; Osteosarcoma RecurrentLast Updated:September 21, 2023Recruiting
Condition(s):Adenocarcinoma of the ProstateLast Updated:August 15, 2019Unknown status
Condition(s):Advanced Pancreatic Cancer; Metastatic Pancreatic CancerLast Updated:October 12, 2023Recruiting
Condition(s):Endometrial CarcinomaLast Updated:November 30, 2020Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.